Exploring key genes and prognostic validation of prostate cancer through transcriptome-wide association study.
TL;DR
The results suggest that ASNS and SUMF2 play important roles in the progression of PC and may serve as candidate prognostic biomarkers associated with PC progression.
Abstract
Prostate cancer (PC) is one of the most common malignant tumors among men worldwide. Although treatment methods for localized PC are relatively well-established, challenges remain due to difficulties in early diagnosis and issues with treatment resistance. This study combines genome-wide association study (GWAS) data with tissue-specific expression quantitative trait loci (eQTL) data through a transcriptome-wide association study (TWAS) to explore key genes associated with PC. The study also includes differential expression analysis and survival analysis to further verify these findings. A total of 46 candidate genes were identified, and survival analysis using the Cancer Genome Atlas Prostate Adenocarcinoma (TCGA-PRAD) dataset revealed that the upregulation of asparagine synthetase (ASNS) is associated with poor prognosis, while the downregulation of sulfatase modifying factor 2 (SUMF2) is linked to adverse prognosis. The results suggest that ASNS and SUMF2 play important roles in the progression of PC and may serve as candidate prognostic biomarkers associated with PC progression.